These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38880956)
1. Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study. Citera G; Mysler E; Kakehasi AM; Pascual-Ramos V; Masson W; Cadatal MJ; Rivas JL; Sheibanie F; Helling C; Ponce de Leon D J Clin Rheumatol; 2024 Aug; 30(5):208-216. PubMed ID: 38880956 [TBL] [Abstract][Full Text] [Related]
2. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Curtis JR; Yamaoka K; Chen YH; Bhatt DL; Gunay LM; Sugiyama N; Connell CA; Wang C; Wu J; Menon S; Vranic I; Gómez-Reino JJ Ann Rheum Dis; 2023 Mar; 82(3):331-343. PubMed ID: 36600185 [TBL] [Abstract][Full Text] [Related]
3. Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients. Charles-Schoeman C; Fleischmann R; Mysler E; Greenwald M; Ytterberg SR; Koch GG; Bhatt DL; Wang C; Mikuls TR; Chen AS; Connell CA; Woolcott JC; Menon S; Chen Y; Lee K; Szekanecz Z Arthritis Rheumatol; 2024 Aug; 76(8):1218-1229. PubMed ID: 38481002 [TBL] [Abstract][Full Text] [Related]
4. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265 [TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a Karpouzas GA; Szekanecz Z; Baecklund E; Mikuls TR; Bhatt DL; Wang C; Sawyerr GA; Chen Y; Menon S; Connell CA; Ytterberg SR; Mortezavi M Ther Adv Musculoskelet Dis; 2023; 15():1759720X231201047. PubMed ID: 37942277 [TBL] [Abstract][Full Text] [Related]
6. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Balanescu AR; Citera G; Pascual-Ramos V; Bhatt DL; Connell CA; Gold D; Chen AS; Sawyerr G; Shapiro AB; Pope JE; Schulze-Koops H Ann Rheum Dis; 2022 Nov; 81(11):1491-1503. PubMed ID: 35922124 [TBL] [Abstract][Full Text] [Related]
7. Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance. Batko B; Jeka S; Wiland P; Zielińska A; Stopińska-Polaszewska M; Stajszczyk M; Kosydar-Piechna M; Cadatal MJ; Rivas JL Rheumatol Ther; 2024 Oct; 11(5):1217-1235. PubMed ID: 39060905 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. Ytterberg SR; Bhatt DL; Mikuls TR; Koch GG; Fleischmann R; Rivas JL; Germino R; Menon S; Sun Y; Wang C; Shapiro AB; Kanik KS; Connell CA; N Engl J Med; 2022 Jan; 386(4):316-326. PubMed ID: 35081280 [TBL] [Abstract][Full Text] [Related]
9. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population. Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906 [TBL] [Abstract][Full Text] [Related]
10. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Charles-Schoeman C; Buch MH; Dougados M; Bhatt DL; Giles JT; Ytterberg SR; Koch GG; Vranic I; Wu J; Wang C; Kwok K; Menon S; Rivas JL; Yndestad A; Connell CA; Szekanecz Z Ann Rheum Dis; 2023 Jan; 82(1):119-129. PubMed ID: 36137735 [TBL] [Abstract][Full Text] [Related]
11. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Wollenhaupt J; Lee EB; Curtis JR; Silverfield J; Terry K; Soma K; Mojcik C; DeMasi R; Strengholt S; Kwok K; Lazariciu I; Wang L; Cohen S Arthritis Res Ther; 2019 Apr; 21(1):89. PubMed ID: 30953540 [TBL] [Abstract][Full Text] [Related]
13. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Kristensen LE; Danese S; Yndestad A; Wang C; Nagy E; Modesto I; Rivas J; Benda B Ann Rheum Dis; 2023 Jul; 82(7):901-910. PubMed ID: 36931693 [TBL] [Abstract][Full Text] [Related]
14. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS; Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665 [TBL] [Abstract][Full Text] [Related]
16. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789 [TBL] [Abstract][Full Text] [Related]
17. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C; Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500 [TBL] [Abstract][Full Text] [Related]
18. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. Claxton L; Taylor M; Soonasra A; Bourret JA; Gerber RA J Manag Care Spec Pharm; 2018 Oct; 24(10):1010-1017. PubMed ID: 29897007 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data. Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375 [TBL] [Abstract][Full Text] [Related]
20. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]